Metabolism of designer drugs of abuse

被引:95
作者
Staack, RF [1 ]
Maurer, HH [1 ]
机构
[1] Univ Saarland, Inst Expt & Clin Pharmacol & Toxicol, Dept Expt & Clin Toxicol, D-66421 Homburg, Saar, Germany
关键词
metabolism; designer drugs; amphetamines; piperazines; pyrrolidinophenones;
D O I
10.2174/1389200054021825
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Abuse of designer drugs is widespread among young people, especially in the so-called "dance club scene" or "rave scene", worldwide. Severe and even fatal poisonings have been attributed to the consumption of such drugs of abuse. However, in contrast to new medicaments, which are extensively studied in controlled clinical studies concerning metabolism, including cytochrome P450 isoenzyme differentiation, and further pharmacokinetics, designer drugs are consumed without any safety testing. This paper reviews the metabolism of new designer drugs of abuse that have emerged on the black market during the last years. Para-methoxyamphetamine (PMA), para-methoxymethamphetamine (PMMA) and 4-methylthioamphetamine (4-MTA), were taken into consideration as new "classical" amphetamine-derived designer drugs. Furthermore, N-benzylpiperazine (BZP), 1-(3, 4-methylenedioxybenzyl)piperazine (MDBP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP), 1-(3-chlorophenyl)piperazine (mCPP) and 1-(4-methoxyphenyl)piperazine (MeOPP) were taken into consideration as derivatives of the class of piperazine-derived designer drugs, as well as alpha-pyrrolidinopropiophenone (PPP), 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), 3', 4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP), and 4'-methyl-alpha-pyrrolidinoexanophenone (MPHP) as derivatives of the class of alpha-pyrrolidinophenone-derived designer drugs. Papers describing identification of in vivo or in vitro human or animal metabolites and cytochrome P450 isoenzyme dependent metabolism have been considered and summarized.
引用
收藏
页码:259 / 274
页数:16
相关论文
共 186 条
[1]   Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives [J].
Bach, MV ;
Coutts, RT ;
Baker, GB .
XENOBIOTICA, 1999, 29 (07) :719-732
[2]   Fatal brain oedema after ingestion of ecstasy and benzylpiperazine [J].
Balmelli, C ;
Kupferschmidt, H ;
Rentsch, K ;
Schneemann, M .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2001, 126 (28-29) :809-811
[3]  
Barbhaiya RH, 1995, EUR J CLIN PHARMACOL, V49, P221
[4]   AN EVALUATION OF CYTOCHROME-P450 ISOFORM ACTIVITIES IN THE FEMALE DARK AGOUTI (DA) RAT - RELEVANCE TO ITS USE AS A MODEL OF THE CYP2D6 POOR METABOLIZER PHENOTYPE [J].
BARHAM, HM ;
LENNARD, MS ;
TUCKER, GT .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (08) :1295-1307
[5]   THE SEROTONIN AGONIST M-CHLOROPHENYLPIPERAZINE (MCPP) BINDS TO SEROTONIN TRANSPORTER SITES IN HUMAN BRAIN [J].
BAUMANN, MH ;
MASH, DC ;
STALEY, JK .
NEUROREPORT, 1995, 6 (16) :2150-2152
[6]   IDENTIFICATION OF 4 METABOLIC PRODUCTS AFTER INCUBATION OF P-METHOXYAMPHETAMINE WITH LIVER PREPARATIONS OF VARIOUS SPECIES [J].
BECKETT, AH ;
MIDHA, KK .
XENOBIOTICA, 1974, 4 (05) :297-311
[7]   THE EFFECTS OF 5-HT1B CHARACTERIZING AGENTS IN THE MOUSE ELEVATED PLUS-MAZE [J].
BENJAMIN, D ;
LAL, H ;
MEYERSON, LR .
LIFE SCIENCES, 1990, 47 (03) :195-203
[8]   Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects [J].
Benjamin, J ;
Greenberg, BD ;
Murphy, DL .
PSYCHOPHARMACOLOGY, 1996, 127 (02) :140-149
[9]  
BENKELFAT C, 1991, ARCH GEN PSYCHIAT, V48, P383
[10]   POSSIBLE SEROTONERGIC AND DOPAMINERGIC MEDIATION OF THE N-ETHYL-3,4-METHYLENEDIOXYAMPHETAMINE DISCRIMINATIVE STIMULUS [J].
BOJA, JW ;
SCHECHTER, MD .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 202 (03) :347-353